Tirzepatide hydrochloride

• CAT Number: I046062
• Molecular Formula: C225H348N48O68.xHCl
• Molecular Weight: 4813.45 (free base)
• Purity: ≥95%
• Target: Glucagon-Like Peptide 1 (GLP-1) Receptor

Tirzepatide hydrochloride (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide hydrochloride has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity[1][2][3].
Tirzepatide hydrochloride (0-0.4 μM, 7 days) is used to improve the neurodegeneration of SHSY5Y human neuroblastoma cells induced by high glucose and to overcome neuronal insulin resistance[1].
Tirzepatide hydrochloride (10 nmol/kg, subcutaneous injection) can inhibit colon cancer tumor growth in dietary-obese mice[2].
Tirzepatide hydrochloride (1.35 mg/kg, intraperitoneal injection, once per week) improves spatial learning and memory impairment by modulating abnormal insulin resistance and inflammatory response in diabetic rats[3].

Reference

[1]. Fontanella RA, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024 Jan 29;22(1):114.
[Content Brief]

[2]. Huang L, et al. Tirzepatide inhibits tumor growth in mice with diet-induced obesity. bioRxiv, 2023: 2023.06. 22.546093.

[3]. Guo X, et al. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Front Pharmacol. 2023 Aug 28;14:1146960.
[Content Brief]